Predictors of venous thromboembolism recurrence, adjusted for treatments and interim exposures: a population-based case-cohort study.

[1]  M. Streiff.  Predicting the risk of recurrent venous thromboembolism (VTE) , 2015, Journal of Thrombosis and Thrombolysis.

[2]  G. Agnelli,et al.  Prophylaxis against venous thromboembolism in patients with cancer. , 2014, The New England journal of medicine.

[3]  P. Prandoni,et al.  D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. , 2014, Blood.

[4]  K. Bailey,et al.  Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study. , 2014, Blood.

[5]  E. Akl,et al.  Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. , 2014, Blood.

[6]  P. Kyrle,et al.  Predicting the risk of recurrent venous thromboembolism , 2013, Hämostaseologie.

[7]  C. Tromeur,et al.  Lipid lowering drugs and the risk of recurrent venous thromboembolism. , 2012, Thrombosis research.

[8]  D. Xavier,et al.  Low-dose aspirin for preventing recurrent venous thromboembolism. , 2012, The New England journal of medicine.

[9]  J. Douketis,et al.  Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) , 2012, Journal of thrombosis and haemostasis : JTH.

[10]  W. Ageno,et al.  Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.

[11]  J. Heit.  Predicting the risk of venous thromboembolism recurrence , 2012, American journal of hematology.

[12]  B. Yawn,et al.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. , 2012, Mayo Clinic proceedings.

[13]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[14]  K. Bailey,et al.  Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study. , 2011, Blood.

[15]  Giancarlo Agnelli,et al.  Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials , 2011, BMJ : British Medical Journal.

[16]  B. Yawn,et al.  American Journal of Epidemiology Practice of Epidemiology Use of a Medical Records Linkage System to Enumerate a Dynamic Population over Time: the Rochester Epidemiology Project , 2022 .

[17]  Mary Cushman,et al.  Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis , 2011, BMJ : British Medical Journal.

[18]  P. Wells,et al.  Development of a Clinical Prediction Rule for Risk Stratification of Recurrent Venous Thromboembolism in Patients With Cancer-Associated Venous Thromboembolism , 2010, Circulation.

[19]  G. Leftheriotis,et al.  Predictive factors for concurrent deep-vein thrombosis and symptomatic venous thromboembolic recurrence in case of superficial venous thrombosis , 2010, Thrombosis and Haemostasis.

[20]  Georg Heinze,et al.  Risk Assessment of Recurrence in Patients With Unprovoked Deep Vein Thrombosis or Pulmonary Embolism: The Vienna Prediction Model , 2010, Circulation.

[21]  K. Bailey,et al.  Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism?: A Population-Based Case–Control Study , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[22]  S. Kahn,et al.  Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy , 2008, Canadian Medical Association Journal.

[23]  Oswald Wagner,et al.  Overweight, obesity, and the risk of recurrent venous thromboembolism. , 2008, Archives of internal medicine.

[24]  M. Schemper,et al.  High-Density Lipoprotein and the Risk of Recurrent Venous Thromboembolism , 2007, Circulation.

[25]  Paolo Prandoni,et al.  The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. , 2007, Haematologica.

[26]  Frits R Rosendaal,et al.  Thrombophilia, clinical factors, and recurrent venous thrombotic events. , 2005, JAMA.

[27]  E. Minar,et al.  The risk of recurrent venous thromboembolism in men and women. , 2004, The New England journal of medicine.

[28]  L. Cristina,et al.  High plasma levels of factor VIII and risk of recurrence of venous thromboembolism , 2004, British journal of haematology.

[29]  P. Romano,et al.  Comparison of Outcomes after Hospitalization for Deep Venous Thrombosis or Pulmonary Embolism , 2002, Thrombosis and Haemostasis.

[30]  H. Arnesen,et al.  Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy , 2000, Thrombosis and Haemostasis.

[31]  T. Gursel,et al.  THROMBOPHILIA , 2000, Pediatric hematology and oncology.

[32]  W E Barlow,et al.  Analysis of case-cohort designs. , 1999, Journal of clinical epidemiology.

[33]  L. Melton,et al.  Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. , 1999, Archives of internal medicine.

[34]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[35]  F. Cirisano,et al.  Apparent heparin resistance form elevated factor VIII in a patient with postoperative deep venous thrombosis. A case report. , 1996, The Journal of reproductive medicine.

[36]  L. Melton,et al.  History of the Rochester Epidemiology Project. , 1996, Mayo Clinic proceedings.

[37]  Steven G. Self,et al.  Asymptotic Distribution Theory and Efficiency Results for Case-Cohort Studies , 1988 .

[38]  G. Raskob,et al.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. , 1986, The New England journal of medicine.

[39]  R. L. Prentice,et al.  A case-cohort design for epidemiologic cohort studies and disease prevention trials , 1986 .

[40]  J. White,et al.  Kaolin partial thromboplastin time: high levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulants. , 1967, The Journal of laboratory and clinical medicine.

[41]  P. Kyrle,et al.  Vorhersage des Rezidivrisikos der venösen Thromboembolie , 2013 .

[42]  W. Ageno,et al.  Abdominal obesity and the risk of recurrent deep vein thrombosis. , 2007, Thrombosis research.

[43]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[44]  M. Szklo,et al.  Population-based cohort studies. , 1998, Epidemiologic reviews.

[45]  A. Champetier de Ribes.  [Overweight]. , 1961, Soins. Pediatrie, puericulture.